ILPLFISLAND PHARMACEUTICALS LTD.

About ISLAND PHARMACEUTICALS LTD. (ILPLF)

ISLAND PHARMACEUTICALS LTD. (ILPLF) is a N/A company headquartered in Camberwell, VA, Australia whose shares trade over-the-counter on the Pink tier.

Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. The company has a research collaboration agreement with Monash University to screen known molecules against host targets; research and development collaboration with Griffith University to screen for active anti-viral molecules in a rational repurposing strategy; and research collaboration agreement with Compounds Australia, a drug library containing various molecules that could be searched for drug re-purposing and pipeline development. It also has a cooperative research and development agreement with the U.S. Army in preparation for its Phase II clinical study for ISLA-101; supply agreement with Catalent for manufacture of Fenretinide softgels for dengue fever trial participants; and right to reference National Cancer Institute IND for Isla101.

ILPLF key facts

Ticker symbol

ILPLF

Market tier

Pink

Headquarters

Camberwell, VA, Australia

Shares outstanding

81,268,468

Reporting standard

International Reporting: ASX - Australian Securities Exchange

Audit status

Audited

Fiscal year end

6/30

Explore more: Pink stocks · OTC stocks starting with I